Companies › Klus Pharma
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sacituzumab Govitecan (SKB264) Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 2 | Non-small Cell Lung Cancer; Solid Tumor; Epithelial Ovarian Cancer | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05816252 | Sacituzumab Govitecan (SKB264) | Phase 2 | Non-small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT05642780 | Sacituzumab Govitecan (SKB264) | Phase 2 | Solid Tumor | Oncology | Nov 2027 |
| NCT04152499 | Sacituzumab Govitecan (SKB264) | Phase 1 | Epithelial Ovarian Cancer | Oncology | Nov 2027 |
iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.